Sprycel (dasatinib), a new oral drug for certain forms of leukemia

August 2006

There's lots of excitement about Sprycel (dasatinib), a new oral drug for certain forms of leukemia.

It's for patients who are resistant to or can't take other treatments...including Gleevec (imatinib).

Sprycel is a tyrosine kinase inhibitor...similar to Gleevec.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote